PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

PromoCell GmbH receives EXCiPACT™ certification as manufacturer of pharmaceutical excipients to Good Manufacturing Practice (GMP) standards

  • New possibilities: tailor-made cell culture media and reagents that fulfil specific regulatory requirements are now available on request
  • A streamlined process for defining regulatory specifications reduces the overall burden for customers, therefore saving cost & time and minimizing overall risk
  • The company’s entire cell culture media and reagents portfolios are covered by the new certification
PromoCell – Helping researchers discover more

PromoCell, one of the leading European manufacturers of human cell culture and cell biology products, has announced to have successfully completed a comprehensive EXCiPACT™ audit that certifies the company as a manufacturer of pharmaceutical excipients to Good Manufacturing Practice (GMP) standards.

The EXCiPACT™ certification scheme for pharmaceutical excipients provides a GMP standard that is accepted worldwide and builds on PromoCell’s existing ISO 9001:2015 quality management system. Furthermore, this certification is also compliant with the widely established ANSI 363:2016 standard. “To achieve EXCiPACT™ GMP certification, PromoCell was required to demonstrate that its pharmaceutical excipients are manufactured according to the GMP guidelines, as well as ensuring compliance in our raw material supply chain, production environment, production processes and storage conditions.,” says Dörte Keimer, Head of Quality Assurance at PromoCell.

The EXCiPACT™ certification brings several benefits to PromoCell’s customers. It minimizes risk by ensuring the high quality of the cell culture media and reagents portfolios when used as pharmaceutical excipients. It also enables PromoCell to attend the growing demand of researchers planning to work under a regulatory environment by providing tailor-made cell culture media and reagents based on these regulatory requirements. “This is achieved by a streamlined definition of raw material specifications and documentation required from our customers, thus reducing the regulatory burden, and ultimately saving cost and time. Thanks to this certification, PromoCell will make important contributions in the transition from research to application,” says Dr. Irma Börcsök, CEO of PromoCell.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026